Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07999415 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| PF-07999415 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-07999415 | BIOLOGICAL | Participants will receive single doses of PF-07999415. |
| Placebo | DRUG | Participants will receive matching placebo. |
Inclusion Criteria: * Male and female participants of non-childbearing potential aged 18 to 65 years, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Body Mass Index (BMI...
PF-07999415 is an investigational monoclonal antibody developed by Pfizer, Inc. It is currently in Phase 1 clinical development. The specific disease or condition it is intended to treat has not been disclosed, and the program sits in a therapeutic area classified as other.
PF-07999415 is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating this monoclonal antibody.
PF-07999415 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The program currently has one active trial, and no completed trials have been reported.
PF-07999415 is being studied in trial NCT06965465, titled a study to learn how different amounts of the study medicine called PF-07999415 are tolerated and act in the body in healthy adults. The trial is Phase 1, active but not recruiting, and enrolled 32 healthy adult participants in Belgium.
The Phase 1 trial NCT06965465 is a randomized, double-blind, placebo-controlled study. It enrolled 32 healthy adult volunteers, ages 18 and older, of all sexes, and is being conducted in Belgium. The study is currently active but not recruiting participants.